Operating
D&A
Medtronic D&A decreased by 11.0% to $748.00M in Q2 2025 compared to the prior quarter. Year-over-year, this metric grew by 13.0%, from $662.00M to $748.00M. Over 4 years (FY 2021 to FY 2025), D&A shows relatively stable performance with a 1.4% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2014
Last reportedQ1 2026Aug 26, 2025
How to read this metric
Higher levels indicate significant capital investment in infrastructure or acquisitions, while lower levels may suggest aging assets or limited capital expenditure.
Detailed definition
This represents the non-cash expense allocated to the cost of tangible and intangible assets over their useful lives. Be...
Peer comparison
High in capital-intensive industries like manufacturing and healthcare devices; lower in service-based sectors.
Metric ID:
depreciation_and_amortization_cfHistorical Data
18 periods
| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $684.00M | $671.00M | $668.00M | $680.00M | $688.00M | $668.00M | $676.00M | $674.00M | $679.00M | $672.00M | $665.00M | $656.00M | $654.00M | $662.00M | $831.00M | $528.00M | $840.00M | $748.00M |
| QoQ Change | — | -1.9% | -0.4% | +1.8% | +1.2% | -2.9% | +1.2% | -0.3% | +0.7% | -1.0% | -1.0% | -1.4% | -0.3% | +1.2% | +25.5% | -36.5% | +59.1% | -11.0% |
| YoY Change | — | — | — | — | +0.6% | -0.4% | +1.2% | -0.9% | -1.3% | +0.6% | -1.6% | -2.7% | -3.7% | -1.5% | +25.0% | -19.5% | +28.4% | +13.0% |
Range$528.00M – $840.00M
CAGR+2.1%
Avg YoY Growth+2.7%
Median YoY Growth-0.7%
Business Segments
| Segment | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Diabetes | $23.50M | $24.00M | $27.00M | $30.00M | $31.00M | $31.00M | $32.00M | $32.00M |
| Cardiovascular | $49.75M | $55.00M | $56.00M | $56.00M | $58.00M | — | — | — |
| Medical Surgical | — | — | — | — | $53.00M | — | — | — |
| Neuroscience | — | — | — | — | $72.00M | — | — | — |
| Other operating segment | — | — | — | — | — | — | — | $0.00 |
| Total | $654.00M | $662.00M | $831.00M | $528.00M | $840.00M | $748.00M | — | — |
D&A at Other Companies
Frequently Asked Questions
- What is Medtronic's d&a?
- Medtronic (MDT) reported d&a of $748.00M in Q2 2025.
- How has Medtronic's d&a changed year-over-year?
- Medtronic's d&a increased by 13.0% year-over-year, from $662.00M to $748.00M.
- What is the long-term trend for Medtronic's d&a?
- Over 4 years (2021 to 2025), Medtronic's d&a has grown at a 1.4% compound annual growth rate (CAGR), from $2.70B to $2.86B.
- What does d&a mean?
- The non-cash accounting expense for the wear and tear or expiration of assets.